Service Corporation International Announces Third Quarter 2009 Financi...(operty and equipment net ...),Health
Navigation Links
Service Corporation International Announces Third Quarter 2009 Financial Results
Date:11/4/2009
operty and equipment, net 1,546,670 1,567,875 Non-current assets held for sale 103,242 97,512 Goodwill 1,175,528 1,178,969 Deferred charges and other assets 368,593 452,634 Cemetery perpetual care trust investments 848,159 744,758 ------- ------- $8,563,197 $8,110,883 ========== ========== Liabilities & Stockholders' Equity Current liabilities: Accounts payable and accrued liabilities $299,934 $294,859 Current maturities of long-term debt 26,061 27,104 Current liabilities held for sale 625 465 Income taxes 1,623 4,354 ----- ----- Total current liabilities 328,243 326,782 ------- ------- Long-term debt 1,717,507 1,821,404 Deferred preneed funeral revenues 600,653 588,198 Deferred preneed cemetery revenues 812,390 771,117 Deferred income taxes 329,956 288,677 Non-current liabilities held for sale 80,181 75,537 Other liabilities 321,992 356,090 Deferred preneed funeral and cemetery receipts held in trust 2,103,825 1,817,665 Care trusts' corpus 849,459 772,234 Stockholders' equity: Common stock, $1 per share par value, 500,000,000 shares authorized, 253,594,517, and 249,953,075 shares issued, respectively, 253,184,884 and 249,472,075 s
'/>"/>
| SOURCE Service Corporation International Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education
2. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
3. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
4. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
5. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
6. Medical Services International Maintains Pace in Second Quarter
7. Area Health Care Providers Announce Plans to Integrate Services
8. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
9. Award-winning QUITPLAN(R) Services Billboard Debuts in Rogers
10. AMN Healthcare Services to Host Analyst Day on Tuesday, September 18, 2007
11. MDS Pharma Services Wins Award for Management of Global Malaria Trial
Post Your Comments:
(Date:11/27/2009)..., BEDFORD, Mass., Nov. 27 /PRNewswire-FirstCall/...ny"), a supplier of precision technology products ... annual meeting of the Company,s shareholders has ...me and location of the meeting will be announced i...y received a requisition notice from Stephen Bersh...
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 ...ed that Blair Lambert, CFO/COO, will present at th...held at the May Fair Hotel in London, England, on ..., To listen to a live broadcast of The Gymboree ...se log on to www.gymboree.com, click on "Our Compa...
(Date:11/27/2009)... XenaCare Holdings has announced t...tis Foundation, one of the largest nonprofit organ...c health education. , Del...e Holdings, Inc. (OTCBB: XCHO), a company speciali...onsumer healthcare products, has announced today t...
(Date:11/27/2009)... Voyant Health™ announced to...has licensed its TraumaCad Enterprise orthopedic t...ow solution. , (PRWEB) No...today that Spectrum Health (Grand Rapids, Michigan... templating solution and its TraumaCad Extend work...
(Date:11/26/2009)..., NEW YORK, Nov. 27 With cold and... to employ good practices to control the spread of...e proactive not only to keep ourselves healthy, bu...id Eileen Finerty, RN, MS, CIC (certified in infec...rol and occupational health at Hospital for Specia...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4[0] GSI Group Calls Shareholders Meeting[0] The Gymboree Corporation to Present at NASDAQ OMX 23rd Investor Program[0] XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation [0] Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend[1] Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use
...ative Legume Research (CILR) have screened legumes...il bacteria// in their roots, for biological activ...ch could potentially prevent the formation of a bl...application for compounds to treat cancer.
...
...th breast cancer in England has started a protest ...rug treatment// at a hospital. Local health boards...like the Shropshire Primary Care Trust. The patien...at breast cancer patients from Wales are getting t...
...ually snoring parents are also at an increased ris...esearchers have also found that children with atop... for chronic snoring.
Sleep-disordered breat...ow becomes obstructed, the throat and tongue vibra...
... Inc., a U.S. biopharmaceutical company, Cesario V... at the Medical College of Georgia in Augusta and ...s into the brains of rats that had suffered stroke...American Academy of Neurology annual meeting, in S...
...hropshire and parts of Wales. Breast cancer patien... drug Herceptin but Welsh women get it for free. /...re Trust in Shropshire refused to pay for Hercepti... for the drug for women living in Wales even if th...
...tage, localized breast cancer new patterns and ris...d that may influence how patients are treated. // ...rom 1988 to 2002 was reviewed by Cancer Research C...t DCIS and LCIS develop.
The authors noted t...
Other Medicine News:Health News:Compounds In Legume May Be Helpful In Treating Cancer 2Health News:Cancer Patients Protest For Free Drug Treatment 2Health News:Snoring Runs in the Family 2Health News:Neurological Damage Can Be Reduced By Stem Cell Transplants 2Health News:Free Herceptin Treatment for Those Who Live Over the Welsh Border 2(Date:11/25/2009)...re/ -- Reportlinker.com announces that a new marke..., Mammography Equipment - A Global Market Per...4330/Mammography-Equipment---A-Global-Market-Persp...er in industrialized as well as developing nations...ammography market. Globally, escalating awareness ...
(Date:11/25/2009)...RNewswire/ -- Cempra Pharmaceuticals Inc. today an...chief executive officer, will present at the Piper...0 a.m. EST, December 1, 2009, at The New York Pala...vide an overview of the company,s two leading anti...-resistant pathogens including MRSA. ,, About ...
(Date:11/25/2009)...Newswire/ -- ChemoCentryx, Inc., announced today...s PROTECT-1 (the Prospective Randomized Oral Thera...t-EN(TM) (CCX282-B) in patients with moderate-to-s...cy with a favorable safety and tolerability profil...ficacy in the reduction of disease severity as def...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 1Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 2Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 3SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 10712 1SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 10712 2Study Links Yo Yo Dieting to Addiction 61264 1Study Links Yo Yo Dieting to Addiction 61264 2Study Links Yo Yo Dieting to Addiction 61264 3...E: SHP,Nasdaq: SHPGY), the global specialty biopha...ientific meeting findings from analyses of pivotal...onist. This compound is an,investigational once-da...reatment of the symptoms of Attention Deficit Hype...hat INTUNIV showed significant efficacy in,reducin...
... Expected at ASCO in June -, SOUTH SAN FRANCISCO,...daq: PARD ), a biopharmaceutical company focused,... patient enrollment in,its Phase 2 clinical trial ... the first-line treatment of metastatic colorectal...cted in the second half of 2008. Picoplatin,the Co...
Other Medicine Technology:Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 2Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 3Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 4Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 5Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 6Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 2Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 3Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 4HbA1c/Hb Calibrator Series
STA HEPANORM H
STA HEPARIN CONTROL
STA COAG CONTROL N + ABN
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |